Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. This system comes with optional glucose alarms ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...

Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...

AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. The approval is likely to widen this Illinois-based medical ...

Abbott’s (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across ...

ABBOTT PARK, Ill., Sept. 27, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre Flash Glucose Monitoring System ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Coverage means more Canadians with diabetes can access Abbott's sensor-based glucose technology, giving them actionable insights to manage their condition confidently, i "Sensor-based glucose ...